The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability.

A survival analysis with a mean follow-up of 80.4 months calculated odds ratios (ORs) for incident dementia and cognitive impairment among PET-positive patients, revealing a strong link between ...

Journal of Nuclear Medicine December 2024, jnumed.124.268119; DOI: https://doi.org/10.2967/jnumed.124.268119 ...

"Our study showed that higher visceral fat was associated with higher PET levels of the two hallmark pathologic proteins of Alzheimer's disease -- amyloid and tau," Dolatshahi said. "To our ...

Higher levels of visceral fat were correlated with more amyloid plaque in the brains of cognitively normal individuals, according to a study that hints as to why individuals with obesity are more ...

AD should be treated as a clinical-biological construct, according to the IWG, not a purely biologic construct, per the AA.

"The study also used gold-standard amyloid positron emission tomography, or PET, scans to verify the presence of amyloid and tau in the brains of study participants, and magnetic resonance imaging ...

Plasma p-tau217 immunoassay offers accurate detection of Alzheimer’s disease pathology, supporting early diagnosis and ...

Eli Lilly and Company today announced that the National Medical Products Administration (NMPA) in China has approved Kisunlatm (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion) ...

A recent study published in the Alzheimer's-related journal Alzheimer's Research & Therapy found that relatively healthy obesity—defined as having no metabolic diseases or only one that meets ...